Cambridge Trust’s Apellis Pharmaceuticals APLS Stock Holding History

Cambridge Trust’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$676K	Hold	11,500	–	–	0.03%	171
2023 Q4	$688K	Hold	11,500	–	–	0.03%	169
2023 Q3	$437K	Buy	11,500 +1,500	+15%	+$65.9K	0.02%	198
2023 Q2	$911K	Hold	10,000	–	–	0.04%	138
2023 Q1	$660K	Hold	10,000	–	–	0.03%	164
2022 Q4	$517K	Hold	10,000	–	–	0.02%	192
2022 Q3	$683K	Hold	10,000	–	–	0.03%	164
2022 Q2	$452K	Hold	10,000	–	–	0.02%	215
2022 Q1	$508K	Hold	10,000	–	–	0.02%	216
2021 Q4	$473K	Buy	+10,000	New	+$394K	0.02%	231

Other funds holding APLS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cambridge Trust's APLS Position: Q1 2024 in Review

Cambridge Trust held its Apellis Pharmaceuticals (APLS) position steady in Q1 2024 at 11,500 shares worth $676K. The position accounts for 0.03% of the portfolio, ranked #171.

Cambridge Trust first reported a position in APLS in Q4 2021 and has held it in 10 quarters since. The position peaked at $911K in Q2 2023. 302 funds tracked by Wall St. Rank hold APLS as of Q1 2024.

Cambridge Trust held 11,500 shares of Apellis Pharmaceuticals worth $676K as of Q1 2024.
Cambridge Trust left its Apellis Pharmaceuticals share count unchanged in Q1 2024.
Apellis Pharmaceuticals made up 0.03% of Cambridge Trust's portfolio in Q1 2024, its #171 holding.
Cambridge Trust first reported a position in Apellis Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
Cambridge Trust's Apellis Pharmaceuticals position peaked at $911K in Q2 2023.
302 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2024.

Based on Cambridge Trust's 13F filing for Q1 2024, filed 30 May 2024.